Manhattan BioSolutions Partners to Advance Taxoids as Innovative ADC Payloads

NEW YORK – June 25, 2024 – PRLog — Manhattan BioSolutions, Inc. (MABS), an emerging biotech company developing new classes of precision biologics for the treatment of advanced cancers, and the Institute of Chemical Biology & Drug Discovery (ICB&DD) at Stony Brook University, led by University Distinguished Professor Iwao Ojima, have signed a Letter of Intent (LOI) to establish a collaboration to develop next-generation antibody-drug conjugate (ADC) therapeutics for the treatment of solid tumors with high unmet medical need.

The joint research program leverages the ICB&DD’s cutting-edge medicinal chemistry platforms, including novel fluorine-containing taxoid payloads with superior potency against drug-resistant cancers and a versatile tumor-targeting drug delivery system utilizing a triazine-based tripod linker. These innovative technologies, protected by patent applications filed by The Research Foundation of the State University of New York, have the potential to enhance the efficacy and selectivity of ADCs. MABS seeks to evaluate these technologies for potential use in its proprietary ADC program targeting a novel tumor-associated glycoprotein that is highly expressed across multiple aggressive solid tumor types while showing limited expression in healthy tissues.

“We are excited to collaborate with the ICB&DD to explore the potential of their innovative technologies in the context of ADC therapy,” said Dr. Borys Shor, CEO of Manhattan BioSolutions. “This partnership brings together our deep experience in ADC development with the innovative taxoid platforms pioneered by Professor Ojima, creating an opportunity to address the limitations of current ADC therapies.”

The MABS and ICB&DD teams will work together to design and evaluate novel ADC candidates with the goal of identifying a promising lead for advancement to preclinical development.

About Manhattan BioSolutions

Manhattan BioSolutions, Inc., is a privately held biotechnology company focused on the development of biologic therapies targeting host defense pathways for the treatment of advanced cancers. The company advances two technology platforms for drug discovery: RNA-degrader proteins, and antibody-drug conjugates (ADCs) – through collaborations with leading academic institutions. Manhattan Bio has established partnerships with the National Cancer Institute (NCI), Stony Brook University, The University at Buffalo, Binghamton University, INSERM, Nascent Biotech, EVQLV, and has been awarded grants by the National Institutes of Health (NIH), the National Science Foundation (NSF), the New Jersey Commission on Science, Innovation and Technology (CSIT), the New York State Center For Biotechnology and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UBCAT). Learn more at and follow Manhattan BioSolutions on LinkedIn ( or Twitter (